U.S. Markets closed

Perrigo Company plc (PRGO)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
74.70-1.16 (-1.53%)
At close: 4:02PM EDT

74.40 -0.30 (-0.40%)
After hours: 5:18PM EDT

People also watch
MYLENDPALXNTEVAREGN
Full screen
Previous Close75.86
Open75.89
Bid0.00 x
Ask0.00 x
Day's Range74.68 - 76.00
52 Week Range65.47 - 99.14
Volume1,579,425
Avg. Volume1,844,510
Market Cap10.71B
Beta0.64
PE Ratio (TTM)-3.14
EPS (TTM)-23.8
Earnings DateAug 8, 2017 - Aug 14, 2017
Dividend & Yield0.64 (0.85%)
Ex-Dividend Date2017-05-24
1y Target Est75.87
Trade prices are not sourced from all markets
  • The Wall Street Journal5 days ago

    Health-Care Stocks Get a Boost From Senate Bill Rollout

    Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.

  • Perrigo Company Retains Spencer Stuart for CEO Search
    PR Newswire6 days ago

    Perrigo Company Retains Spencer Stuart for CEO Search

    DUBLIN , June 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products ® ", today announced that the Company's Board ...

  • Perrigo Announces the Launch of Generic Equivalents to Derma-Smoothe/FS® Scalp Oil and Body Oil
    PR Newswire6 days ago

    Perrigo Announces the Launch of Generic Equivalents to Derma-Smoothe/FS® Scalp Oil and Body Oil

    TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body Oil (fluocinolone acetonide topical oil, 0.01%). Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body Oil (fluocinolone acetonide topical oil, 0.01%) are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to four weeks. Perrigo CEO John T. Hendrickson stated, "This launch is another example of Perrigo's ability to develop and bring to market important extended topical treatments.